These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 28816644

  • 1. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R, Dandara C, Viljoen M, Rheeders M.
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [Abstract] [Full Text] [Related]

  • 2. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C.
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [Abstract] [Full Text] [Related]

  • 3. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    Ngayo MO, Oluka M, Kwena ZA, Bulimo WD, Okalebo FA.
    PLoS One; 2022 Aug; 17(3):e0260872. PubMed ID: 35235559
    [Abstract] [Full Text] [Related]

  • 4. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, Shen L, Ma Q, Lu H, Cai W.
    PLoS One; 2015 Aug; 10(6):e0130583. PubMed ID: 26107645
    [Abstract] [Full Text] [Related]

  • 5. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, Maartens G, Haas DW.
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [Abstract] [Full Text] [Related]

  • 6. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
    Gengiah TN, Botha JH, Yende-Zuma N, Naidoo K, Abdool Karim SS.
    Antivir Ther; 2015 Jul; 20(3):297-306. PubMed ID: 25318122
    [Abstract] [Full Text] [Related]

  • 7. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
    Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M.
    Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
    [Abstract] [Full Text] [Related]

  • 8. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH.
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [Abstract] [Full Text] [Related]

  • 9. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A, German Competence Network for HIV/AIDS.
    J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
    [Abstract] [Full Text] [Related]

  • 10. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W.
    Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
    [Abstract] [Full Text] [Related]

  • 11. Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
    Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay M, Moorthy GS, Ratshaa BR, Han X, Steenhoff AP, Mosepele M, Strom BL, Aplenc R, Bisson GP, Gross R.
    J Acquir Immune Defic Syndr; 2017 Aug 01; 75(4):488-491. PubMed ID: 28481785
    [Abstract] [Full Text] [Related]

  • 12. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
    Liu X, Ma Q, Zhao Y, Mu W, Sun X, Cheng Y, Zhang H, Ma Y, Zhang F.
    Pharmacotherapy; 2017 Sep 01; 37(9):1073-1080. PubMed ID: 28718515
    [Abstract] [Full Text] [Related]

  • 13. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
    Luo M, Chapel S, Sevinsky H, Savant I, Cirincione B, Bertz R, Roy A.
    Antimicrob Agents Chemother; 2016 Jun 01; 60(6):3676-86. PubMed ID: 27067333
    [Abstract] [Full Text] [Related]

  • 14. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.
    Antimicrob Agents Chemother; 2013 Feb 01; 57(2):1019-24. PubMed ID: 23254426
    [Abstract] [Full Text] [Related]

  • 15. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
    Paganotti GM, Russo G, Sobze MS, Mayaka GB, Muthoga CW, Tawe L, Martinelli A, Romano R, Vullo V.
    Infect Genet Evol; 2015 Oct 01; 35():122-6. PubMed ID: 26247717
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
    Soeria-Atmadja S, Österberg E, Gustafsson LL, Dahl ML, Eriksen J, Rubin J, Navér L.
    PLoS One; 2017 Oct 01; 12(9):e0181316. PubMed ID: 28886044
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.
    Antimicrob Agents Chemother; 2014 Oct 01; 58(4):2268-73. PubMed ID: 24492364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.